Group 1 - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between -39.85 million and -26.79 million RMB, representing a decrease of 174.56 million to 187.62 million RMB compared to the previous year, a year-on-year decline of 118.13% to 126.97% [1] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses for 2025 is projected to be between -68.73 million and -45.82 million RMB, reflecting a decrease of 171.21 million to 194.12 million RMB compared to the previous year, a year-on-year decline of 136.54% to 154.82% [1] Group 2 - The CRO industry is experiencing downward pressure on overall sales order prices due to changes in the macro environment and intensified industry competition, leading to a decline in the company's main business gross margin [2] - The company signed new orders amounting to 1.135 billion RMB for the year, an increase of 38.62% year-on-year, with overseas market new orders amounting to 74.77 million RMB [2] - The company is enhancing its overseas market expansion efforts through diversified channels and regional layouts, which is expected to increase the proportion of overseas revenue and support revenue growth [2] - As of the end of 2025, the company's backlog of orders reached 1.248 billion RMB, an increase of 28.23% compared to the end of 2024, laying a solid foundation for future operational development [2]

Group 1 - The core viewpoint of the article is that Yinos (688710.SH) is planning to acquire a controlling stake in Yilinsi to enhance its integrated service solutions in the biopharmaceutical non-clinical research sector [1][2] - The acquisition aims to improve the company's upstream and downstream industry chain layout, establishing a comprehensive service system that covers drug research from early concept validation to industrial incubation [1][2] - Yilinsi, established in February 2004, specializes in clinical trial services, focusing on phases I to IV of new drug clinical trials, pharmacokinetics research, and various clinical trial management services [1][2] Group 2 - This transaction is a strategic move in response to national policies encouraging mergers and acquisitions among listed companies to enhance their core business and industry chain [2] - The acquisition will extend the company's business chain, enhance service segments, and strengthen collaboration among different business units, thereby improving the overall quality of development [2] - Yilinsi is a high-tech enterprise and has a mature system and professional capabilities in the clinical research service field, which will significantly enhance the company's comprehensive service capabilities and competitive edge in the industry [2]

Core Viewpoint - The company is experiencing a decline in net profit and gross margin due to macroeconomic changes and intensified industry competition, but it is focusing on expanding its domestic and international business to drive high-quality growth in core operations. Company Performance - The company's main business includes early-stage drug evaluation, non-clinical research, and clinical testing and translational research [9] - The net profit attributable to shareholders and the net profit after deducting non-recurring gains and losses decreased compared to the same period last year [9] - In 2025, the company signed new orders worth RMB 1.135 billion, a year-on-year increase of 38.62%, with overseas orders amounting to RMB 74.772 million [9] - By the end of 2025, the company's backlog of orders reached RMB 1.248 billion, an increase of 28.23% from the end of 2024 [9] Industry Context - The CRO industry is facing downward pressure on sales order prices due to changes in the macro environment and increased competition [9] - The overall sales performance in the industry is being impacted, leading to a decline in gross margins for companies within the sector [9]

证券代码：688710 证券简称：益诺思 公告编号：2026-004 上海益诺思生物技术股份有限公司 关于筹划股权收购暨关联交易的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 本次交易概述 截至本公告披露日，医工总院直接持有益诺思 29,076,360 股，占益诺思已发 行总股本的 20.62%，医工总院为益诺思控股股东。 医工总院不属于失信被执行人。 公司为一家专业提供生物医药非临床研究服务为主的综合研发服务（CRO） 企业，为全球的医药企业和科研机构提供全方位的符合国内及国际申报标准的新 药研究服务。为进一步完善上下游产业链布局，构建一体化服务解决方案，建立 上海益诺思生物技术股份有限公司（以下简称"公司""益诺思"）与公司 控股股东中国医药工业研究总院有限公司（以下简称"医工总院"）的控股 子公司上海益临思医药开发有限公司（以下简称"益临思"或"目标公司"） 及其股东已签署股权收购相关的意向协议，拟以自有资金收购益临思控股 权，具体交易方案及交易条款以最终签署正式协议为准。 医工总 ...

上海益诺思生物技术股份有限公司 关于2025年年度业绩预告的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 上海益诺思生物技术股份有限公司（以下简称"公司"）财务部门初步测算， 预计 2025 年度将出现亏损，净利润与上年同期相比将下降 50%以上。 公司实现归属于上市公司股东的净利润为-3,984.86 万元到-2,678.89 万元， 与上年同期（法定披露数据）相比，将减少 17,456.47 万元到 18,762.44 万元。 预计 2025 年实现归属于上市公司股东扣除非经常性损益后的净利润为 -6,873.29 万元到-4,582.20 万元，与上年同期（法定披露数据）相比，将减少 17,120.81 万元到 19,411.90 万元。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 证券代码：688710 证券简称：益诺思 公告编号：2026-005 经财务部门初步测算如下：（1）预计 2025 年实现归属于 ...

证券之星消息，益诺思发布业绩预告，预计2025年全年归属净利润亏损2678.89万元至3984.86万元。 公告中解释本次业绩变动的原因为： 益诺思2025年三季报显示，前三季度公司主营收入5.71亿元，同比下降35.33%；归母净利润-1478.81万 元，同比下降111.14%；扣非净利润-3475.94万元，同比下降128.8%；其中2025年第三季度，公司单季 度主营收入1.95亿元，同比下降29.39%；单季度归母净利润40.15万元，同比下降98.92%；单季度扣非 净利润-220.28万元，同比下降107.06%；负债率25.17%，财务费用-587.79万元，毛利率28.34%。 受前期宏观环境变化因素影响及行业竞争加剧的叠加影响，CRO 行业整体销售订单价格承压下行，公 司的主营业务毛利率同比下降，报告期内公司归属于上市公司股东的净利润以及归属于上市公司股东扣 除非经常性损益后的净利润较上年同期出现下滑。 2025 年度，公司加大国内外业务布局力度，通过多维举措驱动核心业务高质量发展。公司全年新签订 单金额为人民币 11.35 亿元，同比上涨 38.62%，其中海外市场新签订单金额为人民币 ...

益诺思公告，预计2025年年度将出现亏损，净利润与上年同期相比将下降50%以上。预计2025年实现归 属于上市公司股东的净利润为-3984.86万元到-2678.89万元，与上年同期相比，将减少1.75亿元到1.88亿 元。预计2025年实现归属于上市公司股东扣除非经常性损益后的净利润为-6873.29万元到-4582.2万元， 与上年同期相比，将减少1.71亿元到1.94亿元。 ...

Market Overview - The medical services sector experienced a decline of 0.25% on January 22, with Chengda Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Stock Performance - Notable gainers in the medical services sector included: - Yinos (688710) with a closing price of 66.35, up 5.96% [1] - Hite Bio (300683) at 30.94, up 4.28% [1] - Puri Eye (301239) at 34.79, up 3.73% [1] - Conversely, significant decliners included: - Chengda Pharmaceutical (301201) at 39.67, down 4.16% [2] - Nanmo Bio (688265) at 48.21, down 3.17% [2] - Pruis (301257) at 66.99, down 2.63% [2] Capital Flow - The medical services sector saw a net outflow of 313 million yuan from institutional investors, while retail investors experienced a net inflow of 89.45 million yuan [2] - The capital flow for specific stocks showed: - Innovation Medical (002173) had a net inflow of 89.74 million yuan from institutional investors [3] - Kanglong Chemical (300759) saw a net inflow of 44.95 million yuan from institutional investors [3] - Chengda Pharmaceutical (301201) had a net outflow of 20.46 million yuan from retail investors [3]

1月20日，益诺思跌5.01%，截至发稿，报61.00元/股，成交6270.98万元，换手率1.11%，总市值86.00亿 元。 资料显示，上海益诺思生物技术股份有限公司位于中国(上海)自由贸易试验区郭守敬路199号106室，成 立日期2010年5月12日，上市日期2024年9月3日，公司主营业务涉及专业提供生物医药非临床研究服务 为主的综合研发服务(CRO)。主营业务收入构成为：非临床96.31%，临床3.42%，其他0.27%。 数据显示，汇添富基金旗下1只基金位居益诺思十大流通股东。汇添富医药保健混合（470006）三季度 新进十大流通股东，持有股数112.15万股，占流通股的比例为1.24%。根据测算，今日浮亏损失约 361.13万元。 汇添富医药保健混合（470006）成立日期2010年9月21日，最新规模24.86亿。今年以来收益8.21%，同 类排名2070/8848；近一年收益35.1%，同类排名3677/8093；成立以来收益166.1%。 汇添富医药保健混合（470006）基金经理为郑磊。 截至发稿，郑磊累计任职时间11年38天，现任基金资产总规模80.93亿元，任职期间最佳基金回报 58 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示: ■ 一、信息披露义务人及一致行动人基本信息 （一）信息披露义务人基本信息 2、本次股东权益变动不涉及信息披露义务人披露权益变动报告书； 3、本次权益变动为持股5%以上非第一大股东减持，不会导致公司控股股东、实际控制人发生变化，不 会对公司治理结构及持续经营产生重大影响。 ■ （二）一致行动人基本信息 信息披露义务人上海翱鹏企业管理中心（有限合伙）不存在一致行动人。 二、权益变动触及1%刻度的基本情况 上海益诺思生物技术股份有限公司（以下简称"公司"）于2026年1月16日收到股东上海翱鹏企业管理中 心（有限合伙）（以下简称"翱鹏合伙"）出具的告知函，翱鹏合伙自2026年1月14日～2026年1月16日期 间通过集中竞价交易方式减持其所持有的公司股份512,000股，占公司总股本的0.36%，减持后持有公司 股份16,900,396股，持股比例为11.99%，权益变动触及《上市公司收购管理办法》《证券期货法律适用 ...